Valdecoxib does not interfere with the CYP2D6 substrate metropolol

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 9, 2006, Pages 397-400

  Werner, Ulrike ^a   Lamprecht, C ^a   Werner, D ^b   Schaefer, S ^c   Wuttke, H ^d   Hinz, B ^a   Fromm, M F ^a   Brune, K ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Department of Cardiology   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Drug interaction; Metoprolol; Parecoxib; Rofecoxib; Valdecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2D6; METOPROLOL; METOPROLOL HEUMANN; ROFECOXIB; VALDECOXIB;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 33750726141     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp44397     Document Type: Article

References (7)

1. DYNASTAT™, parecoxib. [Product Information] Pharmacia Europe EEIG, Sandwich, U.K. Revised February 2005.
2. Bresalier RS, Sandier RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092-1102.
3. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol. 2004; 33: 1-6.
4. Lamprecht C, Werner U, Werner D, Schaefer S, Renner B, Brune K. COX-2 selective inhibitors may reduce heart rate. Am J Cardiol. 2005; 95: 1531-1532.
5. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352: 1081-1091.
6. Werner U, Werner D, Rau T, Fromm M, Hinz B, Brune K. Celecoxib inhibits the metabolism of the CYP2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003; 74: 130-137.
7. Werner U, Werner D, Hinz B, Lambrecht C, Brune K. A liquid chromato-graphy-mass spectrometry method for the quantification of both valdecoxib and etoricoxib in human plasma. Biomed Chromatogr. 2005; 19: 113-118.